Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 795 participants.
Also called NCT01174693
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 795 participants
- Registry
-
NCT01174693
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01174693. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2014-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping
- Acronym
- MAESTRO
- Condition
- Cerebral Infarction
- Intervention (Drug)
- Triflusal
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Gangnam Severance Hospital
- Collaborator
- Myung In Pharmaceutical Company
- Collaborator
- Yonsei University
Record details
- Record id
cardio:ct-nct01174693- Content hash
dbdbe190069cdcb20ca037498b3b61e220b5ed1af1286914f4691287244efdf8